Anhui Shi, MD

Quick facts

Phase 3 pipeline

• atezolizumab or durvalumab · Oncology
  Atezolizumab and durvalumab are monoclonal antibodies that block the PD-L1 protein, preventing cancer cells from evading the immune system.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Anhui Shi, MD portfolio CI brief
• Anhui Shi, MD pipeline updates RSS